Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain

Core Insights - Lexicon Pharmaceuticals is hosting a virtual webcast titled "LX9211 - Changing the Paradigm for Treatment of Neuropathic Pain" on January 28, 2025, from 9:00 a.m. to 11:00 a.m. ET [1] - The event will provide an in-depth overview of LX9211, a novel non-opioid treatment for diabetic peripheral neuropathic pain (DPNP), ahead of the anticipated topline data from the Phase 2b PROGRESS trial [2] - The webcast will feature presentations from Lexicon leadership and an expert panel, along with a Q&A session focused on DPNP [2] Company Overview - Lexicon Pharmaceuticals is a biopharmaceutical company dedicated to pioneering medicines that transform patients' lives, utilizing its Genome5000™ program to study nearly 5,000 genes and identify over 100 protein targets with therapeutic potential [3] - The company has a pipeline of promising drug candidates in various stages of discovery and development, targeting indications such as cardiology, neuropathic pain, and metabolism [3]